Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

ber 31, 2006. Shire has the leading portfolio of products in the US ADHD market.

PENTASA - Ulcerative colitis

US prescriptions of PENTASA for the year to December 31, 2007 were up 3% compared to the same period in 2006 primarily due to a 4% increase in the US oral mesalamine prescription market, offset by a 0.1% decrease in PENTASA's average market share from 17.3% in 2006 to 17.2% in 2007.

Sales of PENTASA for the year to December 31, 2007 were US$176.4 million, an increase of 28% compared to the same period in 2006 (2006: US$137.8 million). Sales growth is higher than prescription growth primarily due to restocking to normal levels in 2007 and the impact of price increases in November 2006 and August 2007.

LIALDA/MEZAVANT - Ulcerative colitis

Shire launched LIALDA in the US oral mesalamine market in March 2007, and by December 31, 2007 LIALDA had reached a market share of 8.0% (average annual market share 3.9%). LIALDA's product sales for the year to December 31, 2007 were US$50.5 million. All initial launch stocks of LIALDA totaling US$34.3 million were recognised into revenue during the year to December 31, 2007.

The product was launched in the UK in November 2007, Canada in January 2008 and further launches are planned in the EU during 2008, subject to the successful conclusion of pricing and reimbursement negotiations. In the UK and Ireland the product will be called MEZAVANT XL and Shire plans to market the product in most other EU countries as MEZAVANT.

Since the launch of LIALDA in March 2007, PENTASA and LIALDA's combined share of the US oral mesalamine prescription market had grown to 24.9% as at December 31, 2007, up from 17.6% as at December 31, 2006.

FOSRENOL - Hyperphosphatemia

FOSRENOL is now available in 25 countries and global sales totalled US$102.2 million for the year to December 31, 2007 (2006: US$44.8 million). Outside the US, FOSRENOL has now been launched in Germany, France, UK,
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
(Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... (Nasdaq: NXXI ), a developer and marketer ... levels, improve cardiovascular health, enhance memory and address chronic ... it redeemed all of its Series I outstanding Convertible ... shares. The Company redeemed 3,594 shares for a total ...
... 5:00 p.m. EDT - SOUTH SAN FRANCISCO, Calif., ... SNSS ) today reported financial results for the fourth ... for the year ended December 31, 2008 was $5.4 ... of December 31, 2008, cash, cash equivalents and marketable ...
... on probiotic microorganismsActive ingredient easily integrated into consumer products ... Association of Dental Research annual conference in Miami ... Germany and MIAMI, April 1 With an eye ... affecting an estimated 5 billion people world-wide, BASF -- ...
Cached Biology Technology:Nutrition 21 Redeems Series I Convertible Preferred Shares 2Nutrition 21 Redeems Series I Convertible Preferred Shares 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 2Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 5Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 6Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 7Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 8Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 9Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 10Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 11BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 2BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 3BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 4BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 5
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... with more corals and fish generate predictably greater levels ... This has important implications for understanding the behaviour of ... monitoring environmental health by listening to reefs. Contrary ... noisy places, with fish and invertebrates producing clicks and ...
... their abilities to counsel patients on a healthy diet and ... to a study by the University of Michigan Cardiovascular Center. ... time, being overweight, and if the doctor had adequate training ... study, published online ahead of print Oct. 1 in ...
... (September 21, 2010) For decades scientists believed ... contact with Homo sapiens , but new ... shows these sturdy ancients could adapt, innovate and ... by anthropologist Julien Riel-Salvatore challenge a half-century of ...
Cached Biology News:Taking the pulse of coral reefs 2Doctor's health habits affect patient counseling 2Neanderthals more advanced than previously thought 2
... The Biomek FX P is ... an,up-to-date hardware design for greater positional accuracy and ... just about any application. It can be configured ... its large deck capacity, the Biomek FX P ...
BD Falcon, microtest ELISA plate 96 well flat-bottom, clear. Polystyrene, nonsterile, no lid (25/sp, 100/ca) Packaging: 25 / pack, 100 / case ...
... GenomeLab GeXP Genetic Analysis System provides high-throughput, ... PCR*. The systems patented priming strategy ... PCR analysis to just a few genes ... more genes per reaction and more samples ...
... electrophoresis hood is a component ... Placed on the transilluminator, it ... and provides a darkroom environment ... lab bench. This 13 x ...
Biology Products: